Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 115261373 | 11526137 | 3 | F | 20110706 | 20160912 | 20150918 | 20160919 | EXP | US-TAKEDA-TPA2012A08303 | TAKEDA | 0.00 | Y | 0.00000 | 20160919 | LW | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 115261373 | 11526137 | 1 | PS | ACTOS | PIOGLITAZONE HYDROCHLORIDE | 1 | Oral | 30 MG, UNK | D | 21073 | 30 | MG | TABLET | ||||||
| 115261373 | 11526137 | 2 | SS | ACTOS | PIOGLITAZONE HYDROCHLORIDE | 1 | Oral | 30 MG, UNK | D | 21073 | 30 | MG | TABLET |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 115261373 | 11526137 | 1 | Type 2 diabetes mellitus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 115261373 | 11526137 | DE |
| 115261373 | 11526137 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 115261373 | 11526137 | Bladder cancer | |
| 115261373 | 11526137 | Metastatic carcinoma of the bladder |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 115261373 | 11526137 | 1 | 200212 | 201105 | 0 | |
| 115261373 | 11526137 | 2 | 201106 | 0 |